Nucleai, a Chicago health-tech startup powered by AI, is hoping to get to clinical trials following a recent raise. The company recently pulled in $14 million in new funding, led by M Ventures, bringing the startup’s total funding to date to $60 million. The Series B extension will allow Nucleai to deploy its AI-powered spatial biomarker technology and deploy its platform to patients for clinical trials.
